Corrigendum: Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein

Front Oncol. 2022 Feb 4:12:853608. doi: 10.3389/fonc.2022.853608. eCollection 2022.

Mariana Nunes^{1

2}, Patrícia M A Silva^{3

4}, Ricardo Coelho⁵, Carla Pinto^{3

6}, Albina Resende^{3

6}, Hassan Bousbaa³, Gabriela M Almeida^{7

8}, Sara Ricardo^{1

4

8}

¹ Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal.
² Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
³ CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies (IINFACTS), Gandra, Portugal.
⁴ TOXRUN, Toxicology Research Unit, University Institute of Health Sciences, Polytechnic and University Cooperative (CESPU), Gandra, Portugal.
⁵ Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
⁶ Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), University of Porto, Porto, Portugal.
⁷ Expression Regulation in Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal.
⁸ Faculty of Medicine from University of Porto (FMUP), Porto, Portugal.

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.752127.].

Keywords: P-glycoprotein; Paclitaxel; chemoresistance; high-grade serous carcinoma; ovarian cancer.